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Abstract
Selective serotonin reuptake inhibitors (SSRIs) were
designed to treat depression by increasing serotonin levels
throughout the brain via inhibition of clearance from the
extracellular space. Although increases in serotonin levels
are observed after acute SSRI exposure, 3–6 weeks of
continuous use is required for relief from the symptoms of
depression. Thus, it is now believed that plasticity in multiple
brain systems that are downstream of serotonergic inputs
contributes to the therapeutic efficacy of SSRIs. The onset of
antidepressant effects also coincides with desensitization of
somatodendritic serotonin autoreceptors in the dorsal raphe
nucleus (DRN), suggesting that disrupting inhibitory feedback
within the serotonin system may contribute to the therapeutic
effects of SSRIs. Previously, we showed that chronic SSRI
treatment caused a frequency-dependent facilitation of sero-
tonin signaling that persisted in the absence of uptake
inhibition. In this work, we use in vivo fast-scan cyclic
voltammetry in mice to investigate a similar facilitation after a
single treatment of the SSRI citalopram hydrobromide. Acute
citalopram hydrobromide treatment resulted in frequency-
dependent increases of evoked serotonin release in the
substantia nigra pars reticulata. These increases were inde-
pendent of changes in uptake velocity, but required SERT
expression. Using microinjections, we show that the fre-
quency-dependent enhancement in release is because of
SERT inhibition in the DRN, demonstrating that SSRIs can
enhance serotonin release by inhibiting uptake in a location
distal to the terminal release site. The novel finding that
SERT inhibition can disrupt modulatory mechanisms at the
level of the DRN to facilitate serotonin release will help future
studies investigate serotonin’s role in depression and moti-
vated behavior.
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Selective serotonin reuptake inhibitors (SSRIs) increase
extracellular serotonin levels by reducing serotonin trans-
porter (SERT) function. These drugs were developed
specifically to treat major depressive disorder, supported by
evidence from the monoamine hypothesis linking abnormally
low serotonin levels to symptoms of depression (Jacobsen
et al. 2012). Although SSRIs increase extracellular serotonin
levels after a single dose, 3–6 weeks elapse before they exert
clinically meaningful antidepressant effects. Because of this
time lapse, it is now believed that SSRI efficacy depends on
plasticity in serotonergic function and its downstream targets
(Blier and de Montigny 1998). This plasticity arises from two
key effects of SSRI exposure: increases in extracellular
serotonin levels, and reduced spontaneous firing of seroton-
ergic neurons (Pineyro and Blier 1999). The former is a
consequence of a functional shift in release and uptake
equilibrium because of reductions in SERT function. The
latter arises because of increased activation of 5-HT1A
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autoreceptors, which inhibit firing of serotonergic neurons
(Blier et al. 1998). Sustained increases in serotonin levels
during chronic SSRI treatment lead to functional desensiti-
zation of these autoreceptors, an effect associated with
reduced 5-HT1A receptor mRNA (Bortolozzi et al. 2012),
which leads to reinstatement of normal spontaneous firing
(Davidson and Stamford 1995). Studies have shown that this
desensitization is a critical component of the antidepressant
responses to chronic SSRI treatment in rodent models
(Bortolozzi et al. 2012; Ferres-Coy et al. 2013).
Up to two-thirds of patients initiating SSRI treatment
experience treatment-resistant depression, and many experi-
ence adverse effects that make continuing treatment unde-
sirable (Trivedi et al. 2006). Developing better therapies for
depression will require a more complete understanding of
serotonin’s role in both mood and motivated behavior. While
the monoamine hypothesis suggests that increases in sero-
tonin levels correspond to increases in mood, serotonergic
activity has also been linked to aversive experiences and
punishment (Daw et al. 2002). However, recent research
shows that the function of serotonin in motivational states
and mood is more complex than traditional models suggest.
Liu et al. (2014) found that selective activation of serotonin-
producing neurons in the dorsal raphe nucleus (DRN) of
mice elicited appetitive behavioral effects, but further studies
by McDevitt et al. (2014) suggest that these effects might be
mediated solely by glutamatergic projections from these
neurons to the VTA. Attempts to describe how serotonergic
neurons respond to and encodes for reward and aversion
have revealed that both modalities alter single-unit activity of
identified serotonergic neurons on multiple timescales
(Cohen et al. 2015). This suggests an intricate interplay
between ambient serotonin levels and bursts of release.
Characterizing this interplay is a step toward understanding
which aspects of SSRI-mediated plasticity are necessary for
mood elevation.
While key studies have correlated activity in serotonergic
neurons with appetitive and aversive experiences and
behavioral responses, none have established a causal link
between activity and serotonin neurotransmission. Dopamine
release can be reliably evoked using optogenetic activation of
VTA dopamine neurons (Tsai et al. 2009), but correspond-
ing evidence is lacking for optically evoked serotonin release
in mammalian models. The rapid, multispike burst-firing that
drives robust dopamine release is not equivalent to the bursts
observed in serotonin neurons in vivo, which occur at up to
100 Hz but in trains of only 2–3 spikes (Hajos et al. 1995;
Gartside et al. 2000). Therefore, interpreting the role of
serotonin signaling in studies that measure or manipulate
neuronal activity is obscured by a lack of information about
the magnitude and dynamics of serotonin release. Fast-scan
cyclic voltammetry (FSCV) is a chemically selective, time-
resolved technique that has been used to characterize the
dynamics and regulation of in vivo serotonin release
measured in the substantia nigra pars reticulata (SNpr), a
region richly innervated with serotonergic terminals without
significant interference from other electroactive neurotrans-
mitters. FSCV has been used to show that serotonin release is
under considerably strict regulation as a consequence of a
highly sensitive, balanced system of SERT, autoreceptor, and
monoamine oxidase activity (Hashemi et al. 2012). SERT
function is a powerful regulator of serotonin signaling, and
when it is disrupted, the consequences can be fatal, as in
serotonin syndrome (Boyer and Shannon 2005).
Previously, we showed that 3 weeks of chronic SSRI
treatment results in a facilitation of serotonin signaling at
higher stimulation frequencies, an effect that was dominated
by changes in release, but not uptake (Dankoski et al. 2014).
This finding suggests that SERT expression and function
have profound effects on multiple aspects of neurotransmis-
sion. In this work, we present the observation that in vivo
serotonin release does not vary with frequency as predicted
by slice measurements (O’Connor and Kruk 1991; Iravani
and Kruk 1997; Bunin and Wightman 1998; Jennings et al.
2010). Surprisingly, acute treatment with an SSRI produced
frequency-dependent serotonin release. We hypothesized that
SERT inhibition facilitated in vivo serotonin release in the
SNpr via a mechanism unrelated to inhibition of terminal
uptake. To test this, we measured the acute effects of the
SSRI citalopram hydrobromide (CIT) on serotonin release
evoked by stimulations of varying frequency and intensity to
enable differentiation between its effects on release versus
uptake (Wightman and Zimmerman 1990). While we
observed no frequency dependence in drug-na€ıve mice,
acute CIT treatment produced frequency-dependent increases
in release. SERT knockout (SERT/) mice displayed a low
level of frequency dependence, but did not demonstrate
frequency-dependent facilitation of serotonin release after
CIT administration, confirming that CIT’s effects on release
amplitude are SERT mediated. By microinfusing CIT into
the DRN, we demonstrated that SERT inhibition at the level
of serotonergic cell bodies was sufficient to drive frequency-
dependent effects of CIT; thus, CIT’s enhancement of
serotonin release can be disassociated from its effects on
terminal uptake. Taken together, the findings support the
hypothesis that dramatic increases in ambient serotonin
levels saturate inhibitory 5-HT1A control over release,
leading to a disinhibition of the response to high-frequency
stimulations. This newly characterized effect of SSRIs may




All experiments were conducted in accordance with protocols
approved by the University of North Carolina at Chapel Hill
(UNC-CH) Institutional Animal Care and Use Committee
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(IACUC protocol no. 12-152.0). Male C57Bl6/J WT (n = 29) and
SERT/ (n = 9, Slc6a4 homozygous knock-out) mice were
received from Jackson Laboratories (Bar Harbor, ME, USA) at
5–6 weeks of age and housed in groups of 4 for a minimum of
2 weeks after arrival. Prior to experiments, mice were drug- and
test-na€ıve. Mice were provided with food and water ad libitum and
kept on a 12-h light cycle.
Electrochemistry
Carbon-fiber microelectrodes were fabricated as previously
described (Cahill et al. 1996). Briefly, carbon fibers (7 lm diam-
eter) were aspirated into a glass capillary (external diameter: 0.6,
internal diameter: 0.4) and pulled on a vertical capillary puller
(Narashige, Tokyo, Japan) so that glass formed a tapered seal with
carbon fiber. The exposed length of carbon fiber was trimmed to
150 lm. To enhance sensitivity to serotonin, Nafion (10% in
methanol) was applied to microelectrodes in a dip-coating process.
Briefly, the tip of each electrode was dipped into Nafion solution
then baked at 70°C for 10 min to evaporate solvent. This process
was repeated seven times to obtain the desired Nafion thickness. All
electrodes were post-calibrated in a flow-injection system to obtain
in vitro calibration factors, as previously described (Hashemi et al.
2009).
Application of waveform, data collection, and electrical stimula-
tion were controlled by Tarheel CV software via an in-house
manufactured potentiostat (UEI, UNC-CH Electronics Facility
Chapel Hill, NC, USA). Voltammetric measurement of in vivo
serotonin release has been previously described (Hashemi et al.
2009). Briefly, a voltage waveform scanning from 0.1 to 1 V at
1000 V/s was applied at a rate of 10 Hz and held at 0.2 V between
scans (Jackson et al. 1995).
In vivo experiments
Mice were anesthetized with urethane (2 mg/g body weight, i.p.)
prior to stereotaxic surgery. Urethane anesthesia was employed
because it has little effect on neurotransmission and cardiovascular
and respiratory functions, and it allows anesthesia to be maintained
consistently over the 4–8 h time period of the experiment. A
stainless steel bipolar stimulating electrode (Plastics One, Roanoke,
VA, USA) was implanted into the DRN (AP: 4.1, ML: 0.0, DV:
2.5 to 2.7 mm from Bregma). A carbon-fiber microelectrode
was lowered into the SNpr (AP 3.2, ML: +1.5, DV 4.0 to
4.2 mm from Bregma). An Ag/AgCl reference electrode was
secured in the contralateral hemisphere. All experiments took place
during the light cycle.
Detection of electrically evoked serotonin was optimized by
moving the stimulating electrode and carbon-fiber microelectrode in
0.1 mm increments within the given coordinate ranges. Following
every experiment, CIT (10 mg/kg, i.p.) was administered to
pharmacologically confirm the signal as serotonin. In SERT/
experiments, where CIT predictably had no effect, high concentra-
tions of evoked serotonin release led to cyclic voltammograms that
were easily identifiable as serotonin. The dose of CIT used with i.p.
injection was selected to be consistent with previously published
studies (Hashemi et al. 2009, 2011, 2012; Dankoski et al. 2014). In
a few experiments, clearance was unaffected by CIT. This was
attributed to likely unsuccessful targeting of the SNpr and/or DRN,
and these experiments were excluded from statistical analyses.
Experiments in which both pre- and post-CIT response to the full
range of stimulation frequencies could not be analyzed because of
noise or other technical issues were also excluded (total experiments
excluded: n = 4).
For microinfusion experiments, a microinjection cannula (custom
guide cannula, 10 mm length; Plastics One) was lowered into the
DRN (AP: 4.1, ML: 0.0, DV: 2.4 from Bregma), and
approximately 5 lL of CIT (12 mM) or vehicle (saline) was ejected
into the targeted region through a microinfusion stylus (33 gauge,
11 mm length; Plastics One). The dose and volume of CIT used for
microinfusion experiments was selected because it produced the
most consistent effects in this acute preparation. After 15 min, the
microinjection needle was removed and the stimulating electrode
was implanted in the same location, as described above. Because of
its close proximity to the cerebral aqueduct, misplacement of the
microinjection needle resulted in brain-wide CIT exposure. This was
apparent as an immediate and dramatic slowing of serotonin
clearance in subsequent recordings in the SNpr, and these exper-
iments were excluded from analyses (n = 6). Uptake response to a
systemic injection of CIT at the end of each experiment served as an
additional validation of microinjection targeting.
Drugs and reagents
Racemic citalopram hydrobromide and urethane were from Sigma-
Aldrich (St Louis, MO, USA). Nafion (5% in mixed alcohols) was
from Sigma-Aldrich and concentrated in a rotovap to replace the
solvents with methanol. Replacing mixed alcohol solvents with
methanol produces a more uniform layer in the dip-coating process
(described above). Intraperitoneal-injected drugs were administered
at a volume of 0.01 mL/g body weight.
Data collection
A stainless steel, bipolar stimulating electrode implanted in the DRN
was used to apply biphasic 350 lA, 4 ms pulse width stimulation
trains, which ranged in frequency from 20 to 60 Hz and ranged in
pulse number from 30 to 180 pulses. Where frequency and pulse
number are not indicated, a default stimulation of 60 Hz, 60 pulses
is used. Frequency range was selected to optimize the accuracy and
consistency of t1/2 and release rate measurements. Frequency-
dependence measurements were collected in the order of descending
frequency. Pulse number range was set by the minimum number of
pulses necessary to obtain a good signal-to-noise ratio. Pulse
number measurements were collected in the order of ascending
pulse number.
A minimum of 180 s elapsed between each stimulation train to
prevent short-term effects of stimulation (e.g. depletion, baseline
instability) from influencing data collection over the experimental
period. After CIT administration, no stimulations were applied for
5 min to reduce incidence of subject death (based on observations
from prior experiments).
Statistical analysis
The unit of analysis in these data is a single animal pre- and post-
drug treatment. Subjects in which both pre- and post-drug data could
not be analyzed because of either lack of response to CIT or
technical issues were excluded from analyses (10 experiments total).
Results are described as average values  SEM except when
representative data is noted. Trends in maximum evoked amplitude
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([5-HT]max), release rate, and clearance half-life (t1/2) were analyzed
using a repeated measures ANOVA with Tukey’s multiple compar-
isons post hoc analysis.
Release rate and t1/2 were obtained from concentration traces
evoked by 20–60 Hz stimulations in each subject. Release rate was
calculated by fitting lines to the increasing serotonin concentration
evoked during the first 2 s of stimulation. Adjustments of the fitting
window of up to 0.1 s were made to avoid stimulation artifacts and
ensure linear behavior (r2 > 0.70). Release rate analysis assumes
that stimulated release follows linear behavior, as predicted by
Michaelis–Menten derived kinetic model of neuromodulator release
(Wu et al. 2001). Decay time (t1/2) was calculated in Clampfit
(Molecular Devices, LLC, Sunnyvale, CA, USA) as the time (in
seconds) that elapse between maximal concentration and half-
maximal concentration. One subject was excluded from pre- and
post-CIT t1/2 analysis because of significant drift after electrical
stimulations. This drift did not affect measurements of [5-HT]max.
Results
Serotonin release evoked in vivo varies with stimulation
pulse number, but not frequency
Serotonin release was measured in SNpr during stimulation
of the DRN. A representative color plot identifies serotonin
evoked by a 325 lA, 60 Hz, 1 s stimulation (Fig. 1a). At the
peak potential for serotonin oxidation (0.77 V; white dashed
line), the concentration varies with time, showing release and
subsequent clearance of evoked serotonin (Fig. 1b).
We previously showed that in contrast to work done in
brain slices, serotonin release in vivo is not frequency-
dependent prior to SSRI administration (Dankoski et al.
2014). To better characterize this finding, we compared
[5-HT]max evoked by DRN stimulations varying in pulse
number and frequency. Varying stimulation frequency
Fig. 1 Serotonin release is not frequency-
dependent in vivo. (a) Representative color
plot showing serotonin release evoked in
SNpr by a 60 Hz, 1 s stimulation of dorsal
raphe nucleus. Color plot shows time versus
waveform voltage, with change in current
in pseudocolor. Stimulus duration indicated
by red bar. Oxidation potential for serotonin
indicated by white dashed line.
(b) Concentration trace obtained at
serotonin’s oxidation potential, scaled
using an in vitro post-calibration. Stimulus
duration indicated by red bar. (c) Average
[5-HT]max evoked by 60 pulse stimulation
trains applied at 20, 30, 40, 50, and 60 Hz.
(d) Average [5-HT]max evoked by stimulation
trains of 30, 60, 90, 120, and 180 pulses at
60 Hz. (e) Average rate of change in
serotonin concentration evoked by 60
pulse stimulation trains applied at 20, 30,
40, 50, and 60 Hz. (f) Average t1/2 for these
stimulations. Error bars are  SEM or
+ SEM (n = 5–6).
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in vivo did not affect [5-HT]max (Fig. 1c; One-way ANOVA,
F(4,20) = 1.004, p = 0.43); released concentrations at
20 Hz also did not differ significantly from those at 60 Hz
(15.11  0.94 nM and 16.49  2.32 nM, respectively).
However, [5-HT]max was significantly affected by varying
stimulation pulse number (Fig. 1d; One-way ANOVA,
F(4,16) = 9.374, p < 0.001). Thus, serotonin release evoked
in vivo could be manipulated by varying stimulation pulse
number, but not frequency.
We next examined how stimulation frequency affected t1/2
and release rate evoked by varying stimulation frequencies.
Contrary to the predictions of simple modeling of neuro-
transmitter release (Wightman et al. 1988; Dreyer and
Hounsgaard 2013), release rate did not vary with stimulation
frequency (Fig. 1e; One-way ANOVA, F(4,20) = 0.673,
p = 0.62). Release rate driven by the slowest stimulation
frequency was not significantly different from release rate
driven by the most rapid stimulation frequency (20 Hz:
4.11  0.46 nM/s, 60 Hz: 4.47  0.89 nM/s). As predicted
by the model, t1/2 also did not vary with frequency (Fig. 1f;
One-way ANOVA, F(4,16) = 1.361, p = 0.29). Clearance
following 20 Hz stimulations had similar values to clearance
following 60 Hz stimulations (2.63  0.62 s and
3.44  0.66 s, respectively). These results suggest that
serotonin neurons might reduce sensitivity to high-frequency
stimuli that drive serotonin release.
SERT inhibition enhances serotonin release in a frequency-
dependent manner
Next, we examined CIT’s effects on neurotransmission
dynamics. A duration of 30 min after CIT administration,
[5-HT]max and t1/2 had both increased relative to baseline,
consistent with previous reports (Hashemi et al. 2012;
Dankoski et al. 2014). Table S1 compares average pre-
and post-CIT [5-HT]max, release rate, and t1/2 values. In
Fig. 2(a) and (b), the effects of CIT are apparent in the
serotonergic response to 20 Hz, 60 pulse and 60 Hz, 60
pulse stimulations compared to baseline release. Surpris-
ingly, differences in the magnitude of response to CIT varied






Fig. 2 Citalopram induces frequency-
dependent serotonin release. (a) (i)
Representative color plot showing
serotonin release evoked in SNpr by a
20 Hz, 3 s dorsal raphe nucleus (DRN)
stimulation. (ii) Averaged concentration
trace showing serotonin release evoked by
20 Hz stimulation at baseline (black line)
and 30 min after citalopram hydrobromide
(CIT) treatment (blue line) (b) (i)
Representative color plot showing
serotonin release evoked in SNpr by a
60 Hz, 1 s DRN stimulation. (ii) Averaged
concentration trace showing serotonin
release by 60 Hz stimulation at baseline
(black line) and 30 min after CIT treatment
(blue line). (c) Average [5-HT]max evoked by
60 pulse stimulation trains applied at 20, 30,
40, 50, and 60 Hz, 30 min after CIT
treatment. Dotted line indicates
approximate [5-HT]max before CIT for
comparison. (d) Rate of release evoked in
wild-type mice by 60 pulse stimulations
varying in frequency from 20 to 60 Hz
following CIT treatment. Dotted line
indicates approximate release rate at
baseline. (e) t1/2 of serotonin evoked by
stimulations of varying frequency following
CIT treatment. Dotted line indicates
approximate t1/2 before CIT. Error bars are
 SEM or + SEM (n = 6).
© 2016 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of
International Society for Neurochemistry, J. Neurochem. (2016) 136, 1131--1141
Acute SSRIs amplify serotonin via regulation of DRN 1135
significantly varied with stimulation frequency, exhibiting
robust frequency dependence (Fig. 2c; One-way ANOVA,
F(4,20) = 16.56, p < 0.0001). To determine which aspects
of neurotransmission contributed to CIT-induced frequency
dependence, we analyzed release rate and t1/2 after acute
CIT treatment. The rate of evoked release became signifi-
cantly frequency-dependent (Fig. 2d; One-way ANOVA,
F(4,20) = 24.18, p < 0.0001), and release rate was signifi-
cantly different between 20 Hz and 60 Hz stimulations
(7.62  2.11 nM/s vs. 22.08  4.50 nM/s, paired t-test,
p < 0.01). While t1/2 was increased following CIT, it did
not vary with stimulation frequency (Fig. 2e; One-way
ANOVA, F(4,16) = 1.402, p = 0.28). Uptake after 20 Hz
stimulations was not significantly different from uptake after
60 Hz stimulations (10.88  1.35 s vs. 12.80  1.36 s,
respectively). Together, these results suggest that CIT
treatment altered mechanisms that limit serotonin release,
an effect that may be an important component of SSRIs’
therapeutic effects.
The ability of uptake inhibitors to enhance serotonin release
is SERT-selective
SSRIs slow serotonin clearance by inhibiting its transporter,
SERT. To determine whether CIT affects serotonin release
by a mechanism not involving SERT, we administered CIT
to mice lacking the gene encoding SERT (SERT/ mice).
Baseline serotonin release in SERT/ mice was frequency-
dependent (Fig. 3a, One-way ANOVA, F(4,32) = 10.91,
p < 0.05), and CIT did not increase [5-HT]max or t1/2 relative
to baseline in SERT/ mice (Table S2). When [5-HT]max in
WT+CIT mice was compared to baseline [5-HT]max in
SERT/ mice, there was a significant interaction between
frequency 9 genotype (Fig. 3a; Two-way repeated mea-
sures ANOVA, F(4,52) = 8.701, p < 0.0001. See also Fig. S1).
The effect of genotype on frequency dependence may be as a
result of compensation mechanisms that result from genetic
deletion of SERT, such as changes in serotonin receptor
function and expression (Li 2006; Fox et al. 2008; Moya
et al. 2011), including enhanced 5-HT1A receptor function
in the DRN (Soiza-Reilly et al. 2015), as well as impaired
hypothalamic–pituitary–adrenal axis function (Jiang et al.
2009).
CIT significantly increased t1/2 in wild-type (WT) mice,
but not in SERT/ mice (Fig. 3a, inset, WT: increased by
9.36  1.96 s, SERT/: increased by 1.47  2.40 s).
Thus, we concluded that the effect of CIT on serotonin
release was indeed SERT mediated.
Inhibiting SERT in DRN enhances serotonin release in a
frequency-dependent manner
Data presented above shows CIT effects on [5-HT]max and t1/2
after the effects have stabilized. This occurs approximately
30 min after i.p. administration and remains consistent for up
to 2 h. However, the onset of these effects follows a pattern
Fig. 3 Homozygous SERT knockout (SERT/) function mediates
frequency dependence of serotonin release. (a) Comparison of
average [5-HT]max evoked by 60 pulse stimulations applied at 20, 30,
40, 50, and 60 Hz in citalopram hydrobromide (CIT)-treated wild-type
(WT) mice (gray boxes) and SERT/ mice (green circles). For
comparison, a dotted line indicates approximate baseline [5-HT]max in
WT mice. Inset: Average change in t1/2 following CIT treatment in WT
(gray) and SERT/ mice (green). (b) Average [5-HT]max evoked by
20 Hz, 60 pulse stimulations in CIT-treated WT (black line) and
SERT/ mice (green line). (c) Average serotonin release evoked by
60 Hz, 60 pulse stimulations in CIT-treated WT (black line) and
SERT/ mice (green line).
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that provides additional insights concerning its release-
enhancing mechanisms. To characterize CIT onset, 60 Hz,
60 pulse stimulations were applied at 2 min intervals, and
changes in [5-HT]max and t1/2 relative to pre-drug release
were determined. Fig. 4(a) compares [5-HT]max and t1/2
during the 20 min following i.p. CIT injection (10 mg/kg).
Although t1/2 is not significantly increased until 14 min after
SSRI exposure (14 min time point, p < 0.01), [5-HT]max
significantly increases within the first 6 min (6 min time
point, p < 0.01). Time points that are significantly different
from each measurement’s baseline are indicated on the
graph. Comparison of how the two measurements respond to
Fig. 4 Enhancement of serotonin signaling
by selective serotonin reuptake inhibitors is
mediated by dorsal raphe nucleus (DRN).
(a) Time course of average percent of [5-
HT]max values (blue squares) and t1/2 (red
circles) following acute citalopram
hydrobromide (CIT) treatment with respect
to predrug values. (b) Representative
concentration traces showing serotonin
release 6, 14, and 22 min after acute CIT
treatment. (c) Illustration showing targeting
of the DRN for microinfusions (blue
shading). (d) Comparison of average t1/2
after saline microinfusion (l-SAL; gray) or
CIT microinfusion (l-CIT; blue) before and
after i.p. CIT treatment. (e) Representative
color plot (top) and concentration trace
(bottom) showing release evoked by
60 Hz, 1 s stimulation after lCIT.
(f) Average [5-HT]max following lSAL (gray
circles) and lCIT (blue squares). Error bars
are  SEM or + SEM (n = 4–5). *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001.
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CIT over time found a significant interaction between type of
measurement x time (Fig. 4a; Two-way ANOVA, F(8,72) =
2.174, p < 0.05). Representative traces illustrating the sep-
arate effects on [5-HT]max and t1/2 can be seen in Fig. 4(b).
The apparent disassociation of changes in [5-HT]max from
changes in t1/2 led to a hypothesis that CIT’s effects on
release may be mediated by a different anatomical region
than its effects on terminal region uptake. Since frequency-
dependent effects of CIT on [5-HT]max are not observed in
brain slices (Jennings et al. 2010), where serotonergic
terminals are severed from cell bodies, we hypothesized that
SERT inhibition in DRN contributed to these effects on
electrically evoked release.
To test whether the DRN mediates CIT effects on [5-
HT]max in terminal regions, we microinfused saline (lSAL)
or CIT (lCIT) into the DRN and compared the effects on
evoked serotonin in the SNpr (Fig. 4c). To confirm that
lCIT did not access the cerebral aqueduct and affect SERT
function at the terminal recording site, we compared t1/2 of
serotonin release evoked by 60 Hz stimulations between
lSAL and lCIT before and after a systemic injection of
CIT (10 mg/kg, i.p.). We observed no difference in t1/2
between lSAL and lCIT at baseline or in response to
systemic CIT (Fig. 4f; unpaired t-test, pre-i.p. CIT:
p = 0.62, post-i.p. CIT: p = 0.57). If lCIT affected SERT
in the recording region, t1/2 would not be affected by a
systemic injection of CIT (10 mg/kg, i.p.). t1/2 was signif-
icantly increased by i.p. CIT administration in both lCIT
and lSAL subjects, confirming that lCIT did not alter
SERT function at the terminal recording site (Fig. 4f; Two-
way ANOVA, microinjection treatment: F(1,4) = 0.22,
p = 0.66, i.p. treatment: F(1,4) = 74.01, p = 0.01, interac-
tion: F(1,4) = 2.70, p = 0.18). Thus, microinfusions were
discretely localized and did not alter SERT function in
SNpr.
Next, we compared [5-HT]max evoked by varying stimu-
lation frequencies. Fig. 4(e) shows a representative color plot
and corresponding concentration trace that illustrates the
effects of lCIT on serotonin signaling. [5-HT]max exhibited
frequency dependence following lCIT (Fig. 4f; One-way
ANOVA, F(4,12) = 15.23, p < 0.01). In contrast, [5-HT]max
following lSAL was not frequency-dependent (Fig. 4f; One-
way ANOVA, F(4,12) = 1.19, p = 0.37). When we compared
[5-HT]max between lCIT and lSAL, we observed a
frequency x treatment interaction (Fig. 4f; Two-way repeated
measures ANOVA, F(4,24) = 13.43, p < 0.0001). Post hoc
analyses revealed significant differences between [5-HT]max
in lSAL and lCIT groups at 40 Hz (14.02  1.50 vs.
27.03  3.30 nM, p < 0.01), 50 Hz (15.08  1.21 vs.
32.07  2.61 nM, p < 0.001), and 60 Hz (12.80  0.95
vs. 34.86  4.90 nM, p < 0.0001). Thus, SERT inhibition
in the DRN is sufficient to induce frequency-dependent
enhancement of serotonin release in SNpr, even when local
uptake is normal.
Discussion
Frequency-dependent release is well established for dopa-
mine and norepinephrine (Garris and Wightman 1994; Park
et al. 2009), and it is considered to be a fundamental
component of signaling that transmits information about the
intensity of inputs driving release. The present work
examines the observation that in vivo serotonin release in
the SNpr does not demonstrate frequency dependence in the
same range as other monoamine neurotransmitters. In this
study, we investigate the hypothesis that SERT function
limits how serotonin release responds to high-frequency
stimuli. We first demonstrate that [5-HT]max can be manip-
ulated by altering stimulation intensity, but not stimulation
frequency. Next, we show that acute CIT exposure enhances
serotonin release in a frequency-dependent manner. CIT did
not affect [5-HT]max in SERT
/ mice, indicating that this
enhancement was indeed SERT mediated. Moreover,
SERT/ mice displayed a low level of baseline frequency
dependence, suggesting that genetic loss of the transporter
enabled frequency-dependent signaling in these subjects.
Finally, we show that CIT’s frequency-dependent effects on
release, but not its effects on uptake, are mediated by
inhibition of SERT in the DRN. Together, these results
demonstrate that SERT function in the DRN profoundly
limits how terminal serotonin release responds to high-
frequency stimuli. They also describe a novel mechanism by
which SSRIs can acutely increase serotonin signaling in a
manner that retains information about the stimulus driving
release. This finding may help us better interpret how
serotonin conveys meaningful information about appetitive
and aversive experiences and how SSRI therapies treat
depressive disorders.
Under drug-naïve conditions, serotonin signaling is under
robust regulation from multiple inhibitory elements. The
extent of this regulation is illustrated by a nearly 50-fold
difference between serotonin concentrations evoked in brain
slices versus in vivo in the SNpr (Bunin et al. 1998; John and
Jones 2007; Hashemi et al. 2011). In spite of limited release
in vivo, SERT-mediated uptake rates are comparable between
in vivo and brain slice preparations (Daws and Toney 2007).
Since uptake shapes dynamic neurotransmitter release and
maximal evoked concentrations (Wightman et al. 1988),
these similarities in SERT function predict similarities in
frequency-dependent release. Michaelis–Menten derived
models predict that concentration will increase with stimu-
lation frequency within a physiological range, based on
assumptions that concentration of neurotransmitter released
per pulse, density of transporters (Vmax), and affinity of
transporter for its neurotransmitter (KM) for a given location
in the brain remain constant under drug-na€ıve conditions
(Wu et al. 2001). In addition to these models, studies of
serotonin release in brain slices show frequency-dependent
serotonin release (O’Connor and Kruk 1991; Iravani and
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Kruk 1997; Bunin and Wightman 1998; Jennings et al.
2010). The lack of frequency dependence we report in WT,
drug-na€ıve mice suggests that serotonin release may be
regulated by more complex mechanisms than accounted for
by previous kinetic models and slice experiments.
An important inconsistency between slice and in vivo
serotonin measurements is highlighted in our comparison of
serotonin release in WT versus SERT/ mice. In brain
slices, WT mice exhibit frequency-dependent serotonin
release. Frequency dependence is attenuated in SERT/
mice and after bath application of CIT in WT mice (Jennings
et al. 2010). This finding aligns well with the predictions of a
Michaelis–Menten derived model: since uptake shapes net
evoked serotonin concentration, lack of uptake leads to
similarities in net concentration evoked by every frequency.
In contrast, the results of these in vivo studies found that
genetic deletion of SERT causes frequency dependence
where it was not previously present. One critical difference
between the two experimental preparations is that in vivo
preparations preserve intact circuitry between somatoden-
dritic and axonal locations. Thus, in vivo, regulation at the
level of serotonergic cell bodies contributes to terminal
serotonin release, while slice preparations are able to measure
regulation at the terminal in isolation from somatodendritic
effects. We hypothesize that the same mechanisms promot-
ing frequency-dependent release in CIT-treated WT mice
in vivo promote frequency dependence in SERT/ mice
in vivo. The difference in robustness of the observed
frequency dependence between the two groups may be as a
result of altered serotonergic function in SERT/ mice that
compensates for lack of SERT; notably, enhanced 5-HT1A
feedback to the DRN has been shown in SERT/ mice
(Soiza-Reilly et al. 2015), which may compensate for
decreased function of 5-HT1A receptors within the DRN
(Li 2006).
The mechanism underlying the efficaciousness of SSRIs as
antidepressant therapies has remained somewhat inscrutable
because of methodological inability to resolve their net
effects on serotonin signaling. Microdialysis experiments,
which examine changes in basal extracellular serotonin, have
shown that acute CIT exposure increases ambient levels
approximately 400% in the DRN and nearly 200% in
forebrain terminal regions (Invernizzi et al. 1992). These
increases in extracellular concentration require increases in
serotonergic neuronal firing, but paradoxically, acute CIT
exposure also induces 5-HT1A receptor-mediated decreases
in spontaneous firing of serotonergic neurons (Perry and
Fuller 1992; Gartside et al. 1995; Hajos et al. 1995). The 5-
HT1A receptor, serotonin’s autoreceptor, is known to rapidly
internalize following acute exposure to both serotonin and
CIT (Riad et al. 2001, 2004). This internalization may be
driven by an acute CIT-induced increase in extracellular
serotonin levels that saturates available 5-HT1A receptors. In
contrast, continually elevated serotonin levels during chronic
SERT inhibition may drive more persistent 5-HT1A desen-
sitization and down-regulation of 5-HT1A mRNA in the
DRN. It is this persistent down-regulation of autoreceptors
that is believed to underlie the therapeutic efficacy of SSRIs
(Blier et al. 1998; Bortolozzi et al. 2012). The present
observation of enhanced release after acute CIT treatment
helps reconcile the results of previous microdialysis and
electrophysiological studies. We hypothesize that acute CIT
causes basal serotonin concentrations to saturate 5-HT1A
receptors in the DRN, leaving serotonergic neurons unable to
up-regulate the inhibitory response to phasic inputs, such as
high-frequency electrical stimulations. This results in a
disinhibition of the response to stimulation that enables a
frequency-dependent facilitation of terminal release. Thus,
although basal serotonergic firing rates decrease, activity-
dependent increases in extracellular serotonin levels through-
out the brain can be driven by the DRN’s increased
responsiveness to phasic release-driving stimuli.
Acute SSRI exposure profoundly amplifies serotonin
signaling in an input-coherent manner, but it remains unclear
how amplifying serotonin release influences behavior.
Recently, studies that selectively activate serotonin neurons
using optogenetics in behaving animals have explored
serotonin’s role in motivated behavior. Liu et al. (2014)
found that activating DRN serotonergic neurons is sufficient
to drive real-time place preference and operant responding,
suggesting that increased serotonin release can drive hedonic
and motivated behaviors. However, work by McDevitt et al.
(2014) indicates that glutamate co-released from serotonergic
terminals is required for these DRN-driven behaviors, with
serotonin playing a less critical role. Although serotonin
neurons have been observed burst-firing at 100 Hz in trains
of 2–3 spikes (Jacobs 1991; Hajos et al. 1995; Jacobs and
Fornal 1999), and firing in response to optical stimuli can
follow stimulation frequencies up to 50 Hz in channel-
rhodopsin-expressing serotonin neurons (Liu et al. 2014;
McDevitt et al. 2014), our finding implies that neuronal
response to high-frequency stimuli may not accurately
predict the magnitude of serotonin release. In this study,
higher frequency electrical stimulations did not result in
increased serotonin release in drug-na€ıve mice. More work in
this area is needed to determine to what extent optogenetic
stimulation of serotonergic neurons evokes serotonin release,
and whether this release is physiologically sufficient to drive
appetitive or aversive behaviors.
In this study, we demonstrate a novel mechanism by which
acute SSRIs can amplify serotonin release. Importantly, this
mechanism requires intact circuitry between serotonergic cell
bodies and their terminal release sites, which is uniquely
enabled by in vivo serotonin measurements. The amplifica-
tion of serotonin release is frequency-dependent, retaining
information about the rate of stimulation, and is qualitatively
similar to results observed in animals treated with SSRI for
chronic periods (Dankoski et al. 2014). This similarity
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between acute and chronic responses to SSRIs complicates
how we interpret the role of serotonin in the antidepressant
response. We hypothesize that during initial exposure to
SSRIs, frequency-dependent burst-firing may be masked by
dramatic increases in ambient serotonin levels. As extracel-
lular serotonin levels return to pre-treatment levels over the
chronic treatment period, facilitation of burst-firing may
register as larger, clearer signals throughout the brain. A
recent study by Cohen et al. (2015) in optically identified
serotonergic neurons underscored the importance of both
tonic and phasic firing modes of serotonin neurons. Our work
concurs that a better understanding of these modes, and
SERT’s role in regulating them, may lead to more effective
and expedient methods of treating depressive disorders.
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